Drugs / BIBW2 component B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02203864 | Aug 1998 → Feb 2001 | melanoma | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIBW2 component B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02203864 ↗ |
| Modality | Vaccine | “allogeneic tumor vaccine BIWB 2” NCT02203864 ↗ |
| Route | Other | “four intradermal injections given at two week intervals” NCT02203864 ↗ |